

## Overview

### Useful For

Differentiating hepatocellular carcinomas from other malignancies and hepatic adenomas

### Reflex Tests

Test Id	Reporting Name	Available Separately	Always Performed
IHTOI	IHC Initial, Tech Only	No	No
IHTOA	IHC Additional, Tech Only	No	No

### Testing Algorithm

For the initial technical component only immunohistochemical (IHC) stain performed, the appropriate bill-only test ID will be reflexed and charged (IHTOI). For each additional technical component only IHC stain performed, an additional bill-only test ID will be reflexed and charged (IHTOA).

### Method Name

Immunohistochemistry (IHC)

### NY State Available

Yes

## Specimen

### Specimen Type

TECHONLY

### Ordering Guidance

This test includes only technical performance of the stain (no pathologist interpretation is performed). If diagnostic consultation by a pathologist is required order PATHC / Pathology Consultation.

### Shipping Instructions

Attach the green pathology address label and the pink Immunostain Technical Only label included in the kit to the outside of the transport container.

### Specimen Required

**Supplies:** Immunostain Technical Only Envelope (T693)

**Specimen Type:** Tissue

**Container/Tube:** Immunostain Technical Only Envelope

**Preferred:** 2 Unstained positively charged glass slide (25- x 75- x 1-mm) per test ordered; sections 4-micron thick

**Acceptable:** Formalin-fixed, paraffin-embedded (FFPE) tissue block

### Digital Image Access

1. Information on accessing digital images of immunohistochemical (IHC) stains and the manual requisition form can be accessed through this website: <https://news.mayocliniclabs.com/ihc-stains/>
2. Clients ordering stains using a manual requisition form will not have access to digital images.
3. Clients wishing to access digital images must place the order for IHC stains electronically. Information regarding digital imaging can be accessed through this website: <https://news.mayocliniclabs.com/ihc-stains/#FAQ>

### Forms

If not ordering electronically, complete, print, and send a [Immunohistochemical \(IHC\)/In Situ Hybridization \(ISH\) Stains Request](#) (T763) with the specimen.

### Reject Due To

Wet/frozen tissue Cytology smears Nonformalin fixed tissue Nonparaffin embedded tissue Noncharged slides ProbeOn slides	Reject
--	--------

### Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
TECHONLY	Ambient (preferred)		
	Refrigerated		

### Clinical & Interpretive

#### Clinical Information

Glypican-3 (GPC3) protein is a member of the glypican family of heparin sulfate proteoglycans that are phosphatidylinositol-anchored to the cytoplasmic membrane. GPC3 acts as a coreceptor for heparin-binding growth factors, which play an important role in cell growth and differentiation. Diagnostically, GPC3 will aid in separating hepatocellular carcinomas from other malignancies and hepatic adenomas. It is expressed in 70% to 90% of hepatocellular carcinomas.

---

**Reference Values**

N/A

**Interpretation**

This test does not include pathologist interpretation, only technical performance of the stain. If interpretation is required order PATHC / Pathology Consultation for a full diagnostic evaluation or second opinion of the case.

The positive and negative controls are verified as showing appropriate immunoreactivity and documentation is retained at Mayo Clinic Rochester. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request; call 855-516-8404.

Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

**Cautions**

Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen dependent. Best practice is for paraffin sections to be cut within 6 weeks.

**Clinical Reference**

1. Zhang J, Zhang M, Ma H, et al: Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis. *Medicine (Baltimore)*. 2018;97(2):e11130.
2. Montalbano M, Georgiadis J, Masterson AL: Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma. *Oncol Rep*. 2017 Mar;37(3):1291-1300
3. Haruyama Y, Kataoka H: Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. *World J Gastroenterol*. 2016 Jan 7;22(1):275-283

**Performance****Method Description**

Immunohistochemistry on sections of paraffin-embedded tissue.(Unpublished Mayo method)

**PDF Report**

No

**Day(s) Performed**

Monday through Friday

**Report Available**

1 to 3 days

**Specimen Retention Time**

Until staining is complete.

---

**Performing Laboratory Location**

Rochester

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

**CPT Code Information**

88342-TC, primary

88341-TC, if additional IHC

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
GLYP3	Glypican-3 IHC, Tech Only	Order only;no result

Result ID	Test Result Name	Result LOINC® Value
70760	Glypican-3 IHC, Tech Only	Bill only; no result